Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells <it>in vitro </it>and tumours <it>in vivo</it>
<p>Abstract</p> <p>Background</p> <p>Delivery of small interfering RNA (siRNA) to tumours remains a major obstacle for the development of RNA interference (RNAi)-based therapeutics. Following the promising pre-clinical and clinical results with the oncolytic herpes simp...
Main Authors: | Anesti Anna-Maria, Simpson Guy R, Price Toby, Pandha Hardev S, Coffin Robert S |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-09-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/10/486 |
Similar Items
-
Oncolytic herpes simplex virus and immunotherapy
by: Wenqing Ma, et al.
Published: (2018-12-01) -
Development of replication-defective herpes simplex viral vectors for delivery of RNA interference to neurons of the peripheral nervous system
by: Anesti, A.-M.
Published: (2009) -
Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo
by: Jayeeta Ghose, et al.
Published: (2021-03-01) -
Enhancement of oncolytic herpes simplex type 1 virotherapy
by: Delwar, Zahid M.
Published: (2017) -
Oncolytic Herpes Simplex Virus-Based Therapies for Cancer
by: Norah Aldrak, et al.
Published: (2021-06-01)